All chemicals used in this study along with
their chemical and common names and classifications are listed in Table 1. The NIH Drug Supply
Program provided the following compounds: (+)-lysergic acid diethylamide
hemitartrate (LSD, CAS: 17676-08-3), psilocin (PSI, CAS: 520-53-6),
psilocybin (PSY, CAS: 520-52-5), (−)-ibogaine hydrochloride
(IBO, CAS: 36415-61-9), and (−)-cocaine hydrochloride (COCN,
CAS: 53-21-4). The following compounds were purchased from commercial
sources: (±)-ketamine hydrochloride (KET, Fagron, 803647, CAS:
1867-66-9), (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride
(DOI, Cayman, 13885, CAS: 42203-78-1), (±)-methylenedioxymethamphetamine
hydrochloride (MDMA, Cayman, 13971, CAS: 64057-70-1), and (−)-scopolamine
hydrobromide trihydrate (SCOP, Acros Organics, AC161750010, CAS: 6533-68-2).
The remaining compounds used in these studies were synthesized in
house and judged to be of >95% purity based on nuclear magnetic
resonance
(NMR) and ultrahigh performance liquid chromatography–mass
spectrometry (UHPLC). (±)-Amphetamine fumarate (AMPH) and (±)-3,4-methylenedioxyamphetamine
fumarate (MDA) were prepared using methodology adapted from Nenajdenko
et al.46 (link) (±)-Methamphetamine fumarate
(METH) was prepared as a 1:1 ratio of the enantiopure R- and S-methamphetamine fumarate synthesized as
previously described.47 (link) The vehicle used
for all compounds was molecular biology grade dimethyl sulfoxide (DMSO,
ACROS, AC327182500, CAS: 67-68-5).
Free full text: Click here